331 related articles for article (PubMed ID: 28803366)
1. Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?
Wieringa TH; de Wit M; Twisk JWR; Snoek FJ
J Endocrinol Invest; 2018 Feb; 41(2):249-258. PubMed ID: 28803366
[TBL] [Abstract][Full Text] [Related]
2. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care.
Hajos TR; Pouwer F; de Grooth R; Holleman F; Twisk JW; Diamant M; Snoek FJ
Diabet Med; 2011 Sep; 28(9):1096-102. PubMed ID: 21843305
[TBL] [Abstract][Full Text] [Related]
3. Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy.
Indelicato L; Mariano V; Galasso S; Boscari F; Cipponeri E; Negri C; Frigo A; Avogaro A; Bonora E; Trombetta M; Bruttomesso D
Diabet Med; 2017 May; 34(5):691-697. PubMed ID: 28145047
[TBL] [Abstract][Full Text] [Related]
4. The longitudinal association between glycaemic control and health-related quality of life following insulin therapy optimisation in type 2 diabetes patients. A prospective observational study in secondary care.
Hajos TR; Pouwer F; de Grooth R; Holleman F; Twisk JW; Diamant M; Snoek FJ
Qual Life Res; 2012 Oct; 21(8):1359-65. PubMed ID: 22065281
[TBL] [Abstract][Full Text] [Related]
5. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
6. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
7. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
[TBL] [Abstract][Full Text] [Related]
8. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
10. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
[TBL] [Abstract][Full Text] [Related]
11. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies.
Riddle MC; Vlajnic A; Zhou R; Rosenstock J
Diabetes Obes Metab; 2013 Sep; 15(9):819-25. PubMed ID: 23489438
[TBL] [Abstract][Full Text] [Related]
12. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
[TBL] [Abstract][Full Text] [Related]
15. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD
Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
[TBL] [Abstract][Full Text] [Related]
16. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study.
Polonsky WH; Thompson S; Wei W; Riddle MC; Chaudhari S; Jackson J; Bruno AS
Diabetes Obes Metab; 2014 Nov; 16(11):1121-7. PubMed ID: 24919603
[TBL] [Abstract][Full Text] [Related]
17. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
18. Examining the Behaviour subscale of the Hypoglycaemia Fear Survey: an international study.
Gonder-Frederick LA; Vajda KA; Schmidt KM; Cox DJ; Devries JH; Erol O; Kanc K; Schächinger H; Snoek FJ
Diabet Med; 2013 May; 30(5):603-9. PubMed ID: 23324032
[TBL] [Abstract][Full Text] [Related]
19. The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece.
Pagkalos E; Thanopoulou A; Sampanis C; Bousboulas S; Melidonis A; Tentolouris N; Alexandrides T; Migdalis I; Karamousouli E; Papanas N
Exp Clin Endocrinol Diabetes; 2018 Jan; 126(1):53-60. PubMed ID: 28704857
[TBL] [Abstract][Full Text] [Related]
20. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
Dailey GE; Gao L; Aurand L; Garg SK
Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
